230000000813 microbial Effects 0.000 claims abstract description 6.229960003333 chlorhexidine gluconate Drugs 0.000 claims abstract description 14.YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims abstract description 14.239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19.239000012049 topical pharmaceutical composition Substances 0.000 title claims abstract description 13.229960003600 silver sulfadiazine Drugs 0.000 title claims abstract description 66.C1=CC(N)=CC=C1S(=O)(=O)C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 title claims abstract description 67 UEJSSZHHYBHCEL-UHFFFAOYSA-N Silver sulfadiazine Chemical compound.Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from IN1821DE2010 external-priority Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited Priority to US13/814,086 priority Critical patent/US20130267490A1/en Publication of WO2012017349A2 publication Critical patent/WO2012017349A2/en Publication of WO2012017349A3 publication Critical patent/WO2012017349A3/en Priority to ZA2013/01054A priority patent/ZA201301054B/en Priority to US13/762,792 priority patent/US9433580B2/en Priority to US15/090,985 priority patent/US9572777B2/en Links ( en Inventor Neeta Gupta Simrata Bedi Jyoti Srivastava Vinod Kumar Arora Original Assignee Ranbaxy Laboratories Limited Priority date (The priority date is an assumption and is not a legal conclusion. Google Patents An improved topical pharmaceutical composition comprising nanonized silver sulfadiazineĭownload PDF Info Publication number WO2012017349A2 WO2012017349A2 PCT/IB2011/053263 IB2011053263W WO2012017349A2 WO 2012017349 A2 WO2012017349 A2 WO 2012017349A2 IB 2011053263 W IB2011053263 W IB 2011053263W WO 2012017349 A2 WO2012017349 A2 WO 2012017349A2 Authority WO WIPO (PCT) Prior art keywords pharmaceutical composition silver sulfadiazine composition according sodium acid Prior art date Application number PCT/IB2011/053263 Other languages French ( fr) Google Patents WO2012017349A2 - An improved topical pharmaceutical composition comprising nanonized silver sulfadiazine In addition to these precautions, you may also note that Silver Sulfadiazine Cream is not safe while driving, and is is not addictive in nature.WO2012017349A2 - An improved topical pharmaceutical composition comprising nanonized silver sulfadiazine Refer to the list below for further details. The section on Silver Sulfadiazine Cream contraindications lists all such conditions.ĭrug reaction of Silver Sulfadiazine Cream with other medicines has been reported. Warnings related to Silver Sulfadiazine Cream's effects on the liver, heart and kidney, if any, have been listed below. If, however, they worsen or do not go away, please speak with your physician.įurthermore, you should know that effect of Silver Sulfadiazine Cream is Moderate for pregnant women and Safe for women who are breastfeeding. Usually, these side effects of Silver Sulfadiazine Cream go away soon, and do not persist beyond the duration of the treatment. Some other side effects of Silver Sulfadiazine Cream have been listed ahead. Detailed information has been provided in the dosage section. The condition it has been prescribed for, and the route of administration also determine the right dosage. The correct dosage of Silver Sulfadiazine Cream depends on the patient's age, gender, and medical history. The alternative uses of Silver Sulfadiazine Cream have also been explained below. It is primarily used for the treatment of Burns. Silver Sulfadiazine Cream, a prescription drug, is manufactured in various forms such as Cream.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |